Published in Medical Letter on the CDC and FDA, July 2nd, 2006
The fast-track designation is designed to facilitate the development and potentially expedite the review of new therapeutic medicines intended to treat serious conditions for which there is an unmet medical need.
"The fast track designation is an important step in the regulatory process for the IL-1 Trap, as we come closer to completing the pivotal study,"...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.